Cardiovascular

Correlation between blood pressure (BP) and target organ damage, cardiovascular disease (CVD) risk, and long-term patient prognosis is greater for measurements derived from around-the-clock ambulatory BP monitoring (ABPM) than in-clinic daytime ones. Among the different individual parameters derived from ABPM, the asleep systolic BP (SBP) mean is the most significant independent predictor of CVD events, and, therefore, the recommended parameter to properly diagnose hypertension and determine patient CVD risk.

The progressive decrease in the asleep BP mean, a novel therapeutic target that requires accurate evaluation by ABPM, is a highly significant predictor not only of CVD event-free interval but also of reduction of the risks for new-onset diabetes and development and progression of chronic kidney disease (CKD).

The CAT&D proprietary system enables:

  1. Proper ABPM-derived data analysis and accurate interpretation.
  2. Novel individualized ABPM-based quantification of the risks for CVD events, new-onset diabetes, and development of CKD.
  3. Quantitative assessment, through subsequent routine clinical follow-up by periodic ABPM evaluations, of the effects of therapeutic intervention on such multiple risk scores per individual patient.

Obstetrics

Gestational hypertension (GH) and preeclampsia (PE) are major causes of perinatal morbidity and mortality. Non-invasive around-the-clock ambulatory BP monitoring (ABPM) investigations have documented predictable differences in the 24h BP pattern between pregnant women who during the course of gestation will remain normotensive versus those who will develop GH or PE. In normotensive pregnancies, ambulatory BP steadily decreases until the middle of gestation and thereafter increases slightly until delivery. In contrast, women who will develop GH or PE exhibit stable BP during the first half of pregnancy and afterwards a continuous linear and significantly greater BP increase until delivery.

Prospective studies have consistently documented that ABPM during gestation, commencing preferably at the time of the first obstetric examination following positive confirmation of pregnancy, provides:

  1. sensitive and specific endpoints for early identification of PE and other complications in pregnancy, and
  2. guidance of very low-cost and highly effective prophylactic and/or therapeutic intervention.

Accordingly, ABPM is now recommended as the gold standard for the diagnosis of hypertension in pregnancy and the screening of pregnant women at high risk for other complications of gestation, including preterm delivery, intrauterine growth retardation, and perinatal death.

The CAT&D proprietary system enables:

  1. Proper ABPM-derived data analysis and accurate interpretation.
  2. Early identification of women at high risk of developing hypertensive complications in pregnancy.
  3. Quantitative assessment, through subsequent routine clinical follow-up by periodic ABPM evaluations, of the effects of prophylactic and/or therapeutic intervention on ambulatory BP per individual patient.